Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good morning, and welcome to the MannKind Corporation Second ...

MannKind Corporation (NASDAQ:MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

MannKind Corporation (NASDAQ: MNKD) is one of the best biotech penny stocks to buy right now. Analyst Yun Zhong from Wedbush ...

MannKind 's fourth-quarter conference was only 31 minutes long, but the call contained some tidbits of insight from the biotech's management that investors should know. Source: MannKind.

What: Shareholders of inhaled insulin maker MannKind Corporation are having a rough day. The company's stock is down more than 26% as of 12:30 p.m. EST Tuesday after MannKind reported its first ...

The gig: Hakan Edstrom, 65, is chief executive of MannKind Corp., which developed an inhaled insulin drug that could replace injections for people with diabetes.

Good morning, and welcome to the MannKind Corporation Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded on August 6, 2025, and will be available for ...